论文部分内容阅读
目的:探讨孟鲁司特联合舒利迭治疗重度哮喘的临床疗效。方法:本研究于2010年8月～2012年8月对收治的重度哮喘患者采用孟鲁司特联合舒利迭治疗,并与仅给予舒利迭治疗的对照组进行临床治疗效果及不良反应发生情况比较。结果:研究组的总有效率明显高于对照组,差异具有统计学意义(χ2=5.10,P<0.05)。两组的不良反应发生率无明显差异(x2=0.85,P>0.05)。结论:孟鲁司特联合舒利迭治疗重度哮喘的临床疗效佳,可以明显改善重度哮喘症状和患者的肺功能,不良反应发生率低,值得临床推广使用。
Objective: To investigate the clinical efficacy of montelukast combined with seretide in the treatment of severe asthma. Methods: From August 2010 to August 2012, montelukast combined with seretide was administered to patients with severe asthma admitted to our hospital from August 2010 to August 2012, and the results were compared with those in the control group treated with only seretide Situation comparison. Results: The total effective rate of the study group was significantly higher than that of the control group, the difference was statistically significant (χ2 = 5.10, P <0.05). No significant difference in the incidence of adverse reactions between the two groups (x2 = 0.85, P> 0.05). Conclusion: The montelukast combined with seretide in the treatment of severe asthma has good clinical curative effect, can significantly improve the symptoms of severe asthma and pulmonary function in patients with low incidence of adverse reactions, it is worth promoting the use of the clinic.